ENCell announced on the 28th that it has signed a contract worth about 2 billion won for the contract development and manufacturing (CDMO) of clinical trial drugs with domestic bio pharmaceutical corporations. The contract period extends until July 31, 2026. The key details of the agreement have not been disclosed due to a confidentiality agreement between the two corporations.
ENCell is the top corporation in the domestic cell and gene therapy (CGT) CDMO sector in terms of revenue and market share. ENCell has a pharmaceutical manufacturing and quality control (GMP) facility capable of producing both cells and viruses simultaneously.
Jang Jong-wook, CEO of ENCell, noted, "ENCell continues to provide the best services to clients through optimized processes and quality management to meet the growing domestic and international CDMO demand," adding, "We will strive to establish partnerships with overseas corporations to target the global market."
Meanwhile, ENCell has been collaborating with advanced pharmaceutical development corporations both domestically and internationally by signing successive contract manufacturing agreements with global major pharmaceutical companies, following Novartis and Janssen last December. The company also mentioned that it is working to secure CDMO contracts for adeno-associated virus (AAV), which it has identified as a next-generation growth opportunity.